Opinion|Videos|April 25, 2025
Long-Term Outcomes Assessment
Experts share specific examples of how continuous glucose monitoring (CGM) technology has impacted diabetes-related health care costs and quality performance metrics, and discuss the methods used to measure and track CGM's long-term impact on diabetes complications, associated costs, and quality outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share specific examples of how CGM technology has impacted diabetes-related healthcare costs and quality performance metrics.
- What methods do you use to measure and track CGM's long-term impact on diabetes complications, associated costs, and quality outcomes?
Advertisement
Related to this article
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5